BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia

(2021) Cunte Chen et al.   Frontiers in Pharmacology

BRD4: An Emerging Prospective Therapeutic Target in Glioma

(2021) Hua Yang et al.   Molecular Therapy-Oncolytics

MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination

(2021) Xiaofang Wu et al.   Journal for ImmunoTherapy of Cancer

TOX as a potential target for immunotherapy in lymphocytic malignancies

(2021) Chaofeng Liang et al.   Biomarker Research

Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection

(2021) J. Justin Milner et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion

(2021) Hao Zhang et al.   Journal of Hematology & Oncology

TIM-3 in Leukemia; Immune Response and Beyond

(2021) Mahnaz Rezaei et al.   Frontiers in Oncology

Expression patterns of immune checkpoints in acute myeloid leukemia

(2020) Cunte Chen et al.   Journal of Hematology & Oncology

Regulation of PD-1 in T cells for cancer immunotherapy

(2020) Xibao Yu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Targeting immune checkpoints in hematological malignancies

(2020) Basit Salik et al.   Journal of Hematology & Oncology

News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors

(2020) Ombretta Melaiu et al.   SEMINARS IN CANCER BIOLOGY

Development of Hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma

(2020) Xiaohua Liu et al.   Acta Pharmaceutica Sinica B

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia

(2020) Michael M Boyiadzis et al.   Journal for ImmunoTherapy of Cancer

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2019) Fernando Vieira Pericole et al.   Frontiers in Oncology

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

(2019) Dongxu Wang et al.   Journal of Hematology & Oncology

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

(2019) Weiping Li et al.   Journal of Hematology & Oncology

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

(2019) Omar Khan et al.   NATURE

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses

(2019) Xi Chen et al.   Acta Pharmaceutica Sinica B

TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway

(2019) Yifan Wu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma

(2019) Jiaqiang Ma et al.   Journal for ImmunoTherapy of Cancer

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition

(2019) Wendy Mao et al.   Journal for ImmunoTherapy of Cancer

c-Jun overexpression in CAR T cells induces exhaustion resistance

(2019) Rachel C. Lynn et al.   NATURE

Increased exhausted CD8+ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma

(2018) Jiaxiong Tan et al.   Asia-Pacific Journal of Clinical Oncology

Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword

(2018) Willemijn Hobo et al.   BRITISH JOURNAL OF HAEMATOLOGY

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells

(2018) Chengwu Zeng et al.   Molecular Cancer

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response inKras-Mutant Non–Small Cell Lung Cancer

(2018) Dennis O. Adeegbe et al.   Cancer Immunology Research

BRD4 and Cancer: going beyond transcriptional regulation

(2018) Benedetta Donati et al.   Molecular Cancer

BRD4 interacts with PML/RARα in acute promyelocytic leukemia

(2018) Qun Luo et al.   Frontiers of Medicine

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

(2017) Simon J. Hogg et al.   Cell Reports

Immune Checkpoint Inhibitors: Basics and Challenges

(2017) Bin Li et al.   CURRENT MEDICINAL CHEMISTRY

Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges

(2016) Francesca Tartari et al.   CANCER TREATMENT REVIEWS

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models

(2016) Yuki Kagoya et al.   JOURNAL OF CLINICAL INVESTIGATION

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

(2016) K. E. Pauken et al.   SCIENCE

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

(2016) Hengrui Zhu et al.   Cell Reports

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

(2016) Céline Berthon et al.   Lancet Haematology

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

(2016) Sandy Amorim et al.   Lancet Haematology

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Inhibitory receptors as targets for cancer immunotherapy

(2015) Meghan E. Turnis et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The Transcription Factor NFAT Promotes Exhaustion of Activated CD8 + T Cells

(2015) Gustavo J. Martinez et al.   IMMUNITY

Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+T cells

(2015) Pamela M. Odorizzi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

NF-κB Regulates PD-1 Expression in Macrophages

(2015) Alexander P. R. Bally et al.   JOURNAL OF IMMUNOLOGY

NFATc1 Regulates PD-1 Expression upon T Cell Activation

(2014) K. J. Oestreich et al.   JOURNAL OF IMMUNOLOGY

STAT3, STAT4, NFATc1, and CTCF Regulate PD-1 through Multiple Novel Regulatory Regions in Murine T Cells

(2014) J. W. Austin et al.   JOURNAL OF IMMUNOLOGY

The PD-1/PD-L1 Pathway in Human Pathology

(2012) M. Saresella et al.   CURRENT MOLECULAR MEDICINE

Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1

(2012) G. Xiao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

(2011) Mark A. Dawson et al.   NATURE

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE